72

CLAIMS

1. A compound of formula (I):

$$R^{1} \xrightarrow{O} N - CH_{2} \xrightarrow{OH} CH_{2} - N \xrightarrow{I}_{2} R^{3}$$
 (I)

5 wherein:

 R^1 is phenyl optionally substituted by halogen, cyano, C_{1-4} alkyl or C_{1-4} haloalkyl; R^2 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl; and,

R³ is a group having an NH or OH that has a calculated or measured pKa of 1.0 to 8.0;

or a pharmaceutically acceptable salt thereof.

- 2. A compound of formula (I) as claimed in claim 1 wherein R^1 is phenyl substituted with one, two or three of: halogen, cyano or C_{1-4} alkyl.
- 15 3. A compound of formula (I) as claimed in claim 1 or 2 wherein R² is hydrogen.
 - 4. A compound of formula (I) as claimed in claim 1, 2 or 3 wherein the acidic NH of R³ is part of a ring or part of a substituent on an aryl or heterocyclyl ring.
- 20 5. A compound of formula (I) as claimed in claim 1, 2 or 3 wherein the acidic OH of R³ is a substituent or part of a substituent on an aryl or heterocyclyl ring.
- 6. A compound of formula (I) as claimed in claim 1, 2, 3 or 4 wherein the acidic NH of R³ is part of a suitably substituted 2-oxo-thiazol-5-yl, 2-oxo-oxazol-5-yl, 2-oxo-imidazol-5-yl, 1H-1,2,3-triazol-4-yl, 4-oxo-1H-1,4-dihydropyridin-3-yl, 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl, 6-oxo-1H-1,6-dihydropyridin-3-yl or 2H-tetrazol-5-yl ring.
 - 7. A compound of formula (I) as claimed in claim 1, 2 or 3 wherein R^3 is:
- 2-oxo-thiazol-5-yl having a suitable electron withdrawing substituent in the 4-position;

5

10

15

- 2-oxo-oxazol-5-yl having a suitable electron withdrawing substituent in the 4-position;
- 1H-1,2,3-triazol-4-yl having a suitable substituent in the 5-position;
- 4-oxo-1H-1,4-dihydropyridin-3-yl having a suitable electron withdrawing substituent in the 2-position;
- 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl having a suitable substituent in the 3-position and optionally substituted in one or more other ring positions;
- 6-oxo-1H-1,6-dihydropyridin-3-yl having a suitable electron withdrawing substituent in the 2-position and/or the 5-position and optionally substituted in one or more other ring positions;
- 6-oxo-1H-1,6-dihydropyridin-3-yl having CH₂CO₂H on the ring nitrogen and optionally substituted in one or more other ring positions;
- 2H-tetrazol-5-yl;
- a CO₂H, CH₂CO₂H or OCH₂CO₂H group on an optionally substituted phenyl, optionally substituted CH₂Ophenyl or optionally substituted naphthyl ring; or,
- an NHS(O)₂(C₁₋₄ alkyl) group on an optionally substituted aromatic heterocyclyl ring;

or, where possible, a tautomer thereof.

- 20 8. A compound of formula (I) as claimed in claim 1, 2, 3, 4, 6 or 7 wherein R³ is:
 - 2-oxo-thiazol-5-yl having a suitable electron withdrawing substituent in the 4position;
 - 1H-1,2,3-triazol-4-yl having a suitable substituent in the 5-position; or,
 - 6-oxo-1H-1,6-dihydropyridin-3-yl having C₁₋₄ fluoroalkyl or cyano in the 2-position or the 5-position.
 - 9. A compound of formula (I) as claimed in claim 1, 2, 3, 4, 5, 6, 7 or 8 wherein the 2-hydroxy group has the stereochemistry shown below:

$$R^{1} \stackrel{O}{\underbrace{\hspace{1cm}}} \begin{array}{c} HO_{1} \\ N-C \\ H_{2} \\ H_{2} \\ H_{2} \\ H_{2} \\ H_{2} \end{array} \begin{array}{c} H \\ O \\ R^{3} \\ \end{array} \hspace{1cm} (I)$$

25

5

10

15

10. A process for preparing a compound as claimed in claim 1, the process comprising reacting a compound of formula (II):

$$R^{1}$$
 N
 CH_2
 H
 CH_2
 H
 R^2
 (II)

wherein R¹ and R² are as defined in claim 1, with a compound of formula (III):

$$\begin{array}{c|c}
O \\
L^{1} & R^{3}
\end{array} (III)$$

wherein L^1 is a leaving group, and R^3 is as defined in claim 1; in the presence of a base, optionally in the presence of a coupling agent;

- 11. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier therefor.
 - 12. A compound of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, for use in therapy.
 - 13. A compound of formula (I), or a pharmaceutically acceptable salt thereof as claimed in claim 1, in the manufacture of a medicament for use in therapy.
- 14. A method of treating a chemokine mediated disease state in a mammal suffering
 20 from, or at risk of, said disease, which comprises administering to a mammal in
 need of such treatment a therapeutically effective amount of a compound of
 formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1.